FDA-Approved Prostate Cancer Treatments FDA-Approved Prostate Cancer Treatments – MPR
Generic Brand Strength Form Usual Dose
estramustine Emcyt 140mg caps 14mg/kg in 3 or 4 divided doses
mitoxantrone 2mg/mL soln for IV infusion after dilution 12−14mg/m² every 21 days
abiraterone acetate Yonsa 125mg tabs mCRPC: 500mg once daily (in combination with methylprednisolone 4mg twice daily). Give concurrent GnRH analog or should have had bilateral orchiectomy.
Zytiga 250mg, 500mg tabs 1g once daily on an empty stomach (in combination with oral prednisone 5mg twice daily [mCRPC] or 5mg once daily [mCSPC]). Give concomitant GnRH analog or should have had bilateral orchiectomy.
apalutamide Erleada 60mg tabs CRPC, mCSPC: 240mg once daily. Give concurrent GnRH analog or should have had bilateral orchiectomy.
bicalutamide Casodex 50mg tabs 50mg daily
darolutamide Nubeqa 300mg tabs CRPC: 600mg twice daily. Give concurrent GnRH analog or patient should have had bilateral orchiectomy.
enzalutamide Xtandi 40mg caps CRPC, mCSPC: 160mg once daily. Give concurrent GnRH analog or should have had bilateral orchiectomy.
flutamide 125mg caps 250mg every 8hrs
nilutamide Nilandron 150mg tabs 300mg once daily for 30days, then 150mg once daily, starting day of or day after surgical castration
docetaxel Taxotere 20mg/mL soln for IV infusion after dilution mCRPC: 75mg/m2 once every 3wks with oral prednisone.
cabazitaxel Jevtana 60mg/  1.5mL soln for IV infusion after dilution mCRPC: 20mg/m2 every 3wks, with oral prednisone 10mg/day during treatment; 25mg/m2 may be used in select patients.
sipuleucel‑T Provenge Minimum 50 million autologous CD54+ cells activated with PAP-GM-CSF/ 250mL dose susp for IV infusion Autologous use only. Obtain product release from manufacturer, match patient identity on product and Cell Product Disposition form, check expiration date and time on product before infusing. Premedicate 30min before infusion with acetaminophen and antihistamine. Give three doses at 2‑wk intervals. For each dose: Give entire contents of bag by IV infusion over 60min; do not use filter; do not use if clumps do not disperse with gentle mixing. Observe patient for at least 30min after infusion. May interrupt or slow infusion if acute transfusion reaction occurs; do not restart if product at room temp for >3hrs.
conjugated estrogens Premarin 0.3mg, 0.45mg, 0.625mg, 0.9mg, 1.25mg tabs 1.25−2.5mg 3 times daily
estradiol Estrace 0.5mg, 1mg, 2mg scored tabs 1−2mg 3 times daily
estradiol valerate Delestrogen 10mg/mL, 20mg/mL, 40mg/mL soln for IM inj 30mg or more every 1 or 2wks
estrogens, esterified Menest 0.3mg,  0.625mg, 1.25mg, 2.5mg tabs 1.25−2.5mg 3 times daily
goserelin acetate Zoladex 3.6mg SC implant Advanced prostate cancer: One 3.6mg implant every 28 days or one 10.8mg implant every 12wks. Stage B2-C prostatic carcinoma (in combination with flutamide): Initially one 3.6mg implant, followed in 28 days by one 10.8mg implant; or may use one 3.6mg implant every 28 days. Treat 8wks prior to and during radiotherapy.
Zoladex 3-Month 10.8mg 10.8mg
histrelin acetate Vantas 50mg SC implant Insert 1 implant SC in the inner aspect of the upper arm; remove or replace after 12mos
leuprolide acetate 5mg/mL soln for  SC inj 1mg SC daily
Eligard 7.5mg, 22.5mg, 30mg, 45mg ext-rel susp for SC inj 7.5mg SC once per month; or 22.5mg SC once every 3mos; or 30mg SC once every 4mos; or 45mg SC once every 6mos
Lupron Depot 7.5mg 7.5mg depot susp for IM inj 7.5mg IM once a month (4wks); or 22.5mg IM once every 3mos (12wks); or 30mg IM once every 4mos (16wks); or 45mg IM once every 6mos (24wks)
Lupron Depot–3month 22.5mg 22.5mg
Lupron Depot–4month 30mg 30mg
Lupron Depot – 6month 45mg 45mg
triptorelin pamoate Trelstar 3.75mg, 11.25mg, 22.5mg pwd for IM inj after reconstitution 3.75mg every 4wks or 11.25mg every 12wks or 22.5mg every 24wks
degarelix Firmagon 80mg/  vial, 120mg/  vial pwd for SC inj after reconstitution Give by SC inj in abdomen once every 28 days; avoid waist and rib areas. Two 120mg injections once, then one 80mg inj once every 28 days.
relugolix Orgovyx 120mg tabs 360mg on day 1, then 120mg once daily. If treatment is interrupted for >7days, restart at 360mg, then 120mg once daily.
Poly (ADP-ribose) Polymerase (PARP) Inhibitors
olaparib Lynparza 100mg, 150mg tabs HRR gene-mutated mCRPC: 300mg twice daily until disease progression or unacceptable toxicity.
rucaparib Rubraca 200mg, 250mg, 300mg tabs Deleterious BRCA-mutated mCRPC: 600mg twice daily until disease progression or unacceptable toxicity. Give concurrent GnRH analog or patient should have had bilateral orchiectomy.

KEY: CRPC = castration-resistant prostate cancer; CSPC = castration-sensitive prostate cancer; mCRPC = metastatic castration-resistant prostate cancer; mCSPC = metastatic castration-sensitive prostate cancer

*For palliative treatment only. Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 3/2021)

This article originally appeared on MPR